SRPK1 and prostate carcinoma: Mechanistically, HSP90 inhibition in prostate cancer cells might affect signalling pathways operating upstream of SR proteins like SRSF1 that are involved in AR CE3 splicing inclusion (possibly including effects on the protein kinase SRPK1, see below).